Effect of Diltiazem, a Moderate CYP3A Inhibitor, on the Pharmacokinetics of Anacetrapib, a Potent Cholesteryl Ester Transfer Protein Inhibitor, in Healthy Subjects

被引：15
|
作者：
Garg, Amit [1 ]
Maes, Andrea [1 ]
Corr, Christy [1 ]
Jin, Bo [1 ]
Wadhwa, Tarun [1 ]
Handa, Nikhil [1 ]
Van Dyck, Kristien [1 ]
De Lepeleire, Inge [1 ]
Shah, Jinesh [2 ]
Wagner, John A. [1 ]
Krishna, Rajesh [1 ]
机构：
[1] Merck & Co Inc, Whitehouse Stn, NJ USA
[2] Veeda Clin Res, Ahmadabad, Gujarat, India
来源：
JOURNAL OF CLINICAL PHARMACOLOGY | 2011年 / 51卷 / 03期
关键词：
Cholesteryl ester transfer protein inhibition; CYP3A; diltiazem; CETP INHIBITOR; DRUG-INTERACTION; BLOOD-PRESSURE; 3A ACTIVITY; MIDAZOLAM;
D O I：
10.1177/0091270010368676
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
[No abstract available]
引用
收藏
页码：436 / 439
页数：4
相关论文
共 50 条
  • [21] THE EFFECTS OF THE CYP3A INHIBITOR, ITRACONAZOLE, AND THE CYP3A INDUCER, RIFAMPIN, ON THE PHARMACOKINETICS OF THE MAO-B INHIBITOR, HT-3951, IN HEALTHY SUBJECTS.
    Charriez, C. M.
    Carpenter, D. J.
    Vuppala, P. K.
    Graham, M. A.
    Curtis, C.
    Hoffmann, I.
    Parsons, J. M.
    Ruckle, J.
    Perera, P.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 103 : S62 - S62
  • [22] Mibefradil, a potent CYP3A inhibitor, does not alter pravastatin pharmacokinetics
    Becquemont, L
    Funck-Brentano, C
    Jaillon, P
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 1999, 13 (02) : 232 - 236
  • [23] Lack of 2 clinically meaningful pharmacrikinetic interaction between simvastatin and anacetrapib, a potent chollesteryl ester transfer protein (CETP) inhibitor, in healthy subjects
    Krishna, Rajesh
    Fallon, Marissa
    Jin, Bo
    Keshavarz, Sara Sadeghi
    Zajic, Stefan
    Miksch, Debbie
    Bieberdorf, Frederick A.
    Chodakewitz, Jeffrey
    Wagner, John A.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 48 (09): : 1100 - 1100
  • [24] Single therapeutic and supratherapeutic doses of anacetrapib, a cholesteryl ester transfer protein inhibitor, do not prolong the QTcF interval in healthy volunteers
    Lauring, Brett
    Liu, Yang
    Li, Xiujiang
    Larson, Patrick
    Moreau, Allison
    Farmer, H. Frank
    Johnson-Levonas, Amy O.
    Wagner, John A.
    Lai, Eseng
    JOURNAL OF CLINICAL PHARMACOLOGY, 2014, 54 (07): : 765 - 775
  • [25] Effects of the moderate CYP3A4 inhibitor, fluconazole, on the pharmacokinetics of fesoterodine in healthy subjects
    Malhotra, Bimal
    Dickins, Maurice
    Alvey, Christine
    Jumadilova, Zhanna
    Li, Xiaoxi
    Duczynski, Gregory
    Gandelman, Kuan
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 72 (02) : 263 - 269
  • [26] Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients
    Bloomfield, Daniel
    Carlson, Gary L.
    Sapre, Aditi
    Tribble, Diane
    McKenney, James M.
    Littlejohn, Thomas W., III
    Sisk, Christine McCrary
    Mitchel, Yale
    Pasternak, Richard C.
    AMERICAN HEART JOURNAL, 2009, 157 (02) : 352 - U20
  • [27] Effect of the CYP3A inhibitors, diltiazem and ketoconazole, on ticagrelor pharmacokinetics in healthy volunteers
    Teng, Renli
    Butler, Kathleen
    JOURNAL OF DRUG ASSESSMENT, 2013, 2 (01) : 30 - 39
  • [28] Pharmacokinetic, Pharmacodynamic, and Safety Profile of a New Cholesteryl Ester Transfer Protein Inhibitor in Healthy Human Subjects
    Wolk, R.
    Chen, D.
    Clark, R. W.
    Mancuso, J.
    Barclay, P. L.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 86 (04) : 430 - 437
  • [29] Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib in Japanese patients with heterozygous familial hypercholesterolemia
    Arai, Hidenori
    Teramoto, Tamio
    Daida, Hiroyuki
    Ikewaki, Katsunori
    Maeda, Yuko
    Nakagomi, Mariko
    Shirakawa, Masayoshi
    Kakikawa, Taro
    Numaguchi, Hirotaka
    Johnson-Levonas, Amy O.
    Vaidya, Sanskruti
    Blaustein, Robert O.
    ATHEROSCLEROSIS, 2016, 249 : 215 - 223
  • [30] Pharmacokinetics, Metabolism, and Excretion of Torcetrapib, a Cholesteryl Ester Transfer Protein Inhibitor, in Humans
    Dalvie, Deepak
    Chen, Weichao
    Zhang, Chenghong
    Vaz, Alfin D.
    Smolarek, Teresa A.
    Cox, Loretta M.
    Lin, Jian
    Obach, R. Scott
    DRUG METABOLISM AND DISPOSITION, 2008, 36 (11) : 2185 - 2198
12345